No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VBIV VBI Vaccines
- 0.711
- +0.019+2.75%
Close Jul 2 16:00 ET
- 0.770
- +0.059+8.30%
Post 18:04 ET
20.39MMarket Cap-200P/E (TTM)
0.780High0.685Low384.85KVolume0.700Open0.692Pre Close284.84KTurnover1.44%Turnover RatioLossP/E (Static)28.68MShares1.54052wk High-3.72P/B19.01MFloat Cap0.45052wk Low--Dividend TTM26.73MShs Float2360.907Historical High--Div YieldTTM13.73%Amplitude0.095Historical Low0.740Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting
VBI Vaccines Shows Promise in Glioblastoma Trial
Express News | VBI Vaccines Inc: Expect to Have Additional Tumor Response Data and Initial Survival Data Throughout Remainder of 2024
Express News | VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.
VBI Vaccines' Promising Glioblastoma Treatment Data
Comments
$VBI Vaccines(VBIV.US$
NEWS
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NEWS
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
$VBI Vaccines(VBIV.US$ invest on your own risk, good luck.
$VBI Vaccines(VBIV.US$
NEWS
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. (VBIV) announces a registered direct offering of 2,272,728 common shares at $0.88 per share and unregistered warrants to purchase up to 2,272,728 common shares with an exercise price of $0.76 per share.
NEWS
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
VBI Vaccines Inc. (VBIV) announces a registered direct offering of 2,272,728 common shares at $0.88 per share and unregistered warrants to purchase up to 2,272,728 common shares with an exercise price of $0.76 per share.
2
How Canada's Investment in VBI Vaccines Could Revolutionize Global Health.
In an unprecedented move that underscores the importance of innovation in the fight against infectious diseases, VBI Vaccines Inc. has expanded its strategic partnership with the Government of Canada. This collaboration, supported by a generous funding injection from the Canadian Strategic Innovation Fund (SIF), promises to accelerate the development of grou...
In an unprecedented move that underscores the importance of innovation in the fight against infectious diseases, VBI Vaccines Inc. has expanded its strategic partnership with the Government of Canada. This collaboration, supported by a generous funding injection from the Canadian Strategic Innovation Fund (SIF), promises to accelerate the development of grou...
1
$VBI Vaccines(VBIV.US$ Moving nicely. This is ready. Accumulate
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg